Categories
Business

Recovered Covid sufferers have been reinfected with new virus strains, WHO says

A laboratory technician tests material with a single-channel pipette dropper during processing of the Covid-19 polymerase chain reaction test (PCR) in a laboratory in the South African suburb of Dunkeld in Johannesburg, South Africa on Wednesday, February 10, 2021.

Waldo Swiegers | Bloomberg | Getty Images

Preliminary reports from South Africa show that people who have recovered from Covid-19 have been re-infected with a new, contagious variant of the virus, World Health Organization officials said at a news conference on Friday.

The good news, however, is that vaccines designed to protect against the virus appear to reduce the severity of the disease in those who develop Covid-19, even if they don’t completely protect them from infection, the chief scientist said the WHO, Dr. Soumya Swaminathan.

“The [vaccine] Studies that have so far been carried out in South Africa as well as in Brazil with various candidates have shown complete protection against serious illness, hospitalization and death. A single case was not reported in any of the studies, “she said.

According to the WHO, vaccination can also reduce the spread of new Covid variants.

“There are now reports that when you have the vaccine and you get infected, the viral load is much lower, so you may be less likely to infect others,” Swaminathan said.

Previous Covid infection creates antibodies and cell-mediated immunity that are believed to prevent re-infection, scientists have found. Vaccination also helps individuals build protection against the virus.

However, the researchers are still investigating the extent to which prior infection and vaccination will protect against the new, more infectious variants of the coronavirus.

Increased vaccination efforts alone are unlikely to be enough to control the spread of the UK-native strain of coronavirus, said Dr. Scott Gottlieb, former Commissioner of the Food and Drug Administration, told CNBC on Thursday. Gottlieb said a combination of incoming warmer weather and increased vaccinations could help contain the variant.

Swaminathan at the WHO briefing on Friday stressed the importance of vaccinated people continuing to take precautions such as wearing masks, hand washing and social distancing to control the spread of the virus.

Categories
Business

Dip in Unemployment Claims Gives Hope as New Virus Instances Ease

Following a pandemic-induced surge in layoffs due to new restrictions in many states, unemployment claims are falling, aided by a decline in new coronavirus cases.

Initial unemployment benefits fell last week, the Labor Department reported Thursday, and were well below levels in December and early January.

The number of new coronavirus cases is down a third from two weeks ago, prompting states like California and New York to relax restrictions on indoor eating and other activities. This has given workers in the hardest hit industries some respite.

813,000 new state benefit claims were made last week, compared to 850,000 the previous week. Adjusted for seasonal fluctuations, the value for the last week was 793,000, which corresponds to a decrease of 19,000.

There were 335,000 new entitlements to Pandemic Unemployment Assistance, a government-funded program for part-time workers, the self-employed, and others who are normally not eligible for unemployment benefits. That sum, which was not seasonally adjusted, fell from 369,000 the week before.

While claims remain extraordinarily high by historical standards, the improvement has raised hopes that layoffs will continue to slow as vaccinations spread and employers switch from laying off workers to adding workers.

“We’re stuck with this very high level of damage, but activity is picking up,” said Julia Pollak, employment economist at ZipRecruiter, an online job market. In fact, ZipRecruiter’s job postings are at 11.3 million, near the pre-pandemic 11.4 million level.

The improving pandemic situation has eased the burden on restaurants and bars, Ms. Pollak added. With nearly 10 million jobs deficit since the pandemic started and employers still cautious about hiring, the economy is facing major challenges.

Federal Reserve chairman Jerome H. Powell told the New York Business Club on Wednesday that policymakers should continue to focus on restoring employment, “Given the number of people who have lost their jobs and the likelihood that some struggle to find work in the post-pandemic economy. “

He found that employment for workers earning high wages had fallen by only 4 percent, but for the bottom quartile of those in work it was a “staggering 17 percent”.

Updated

Apr. 11, 2021 at 11:13 am ET

Many other signs of weakness remain. The Ministry of Labor reported that employers only created 49,000 jobs in January, underscoring the challenges facing the unemployed.

President Biden cited the poor performance to call for approval of a $ 1.9 trillion pandemic relief package. It would send $ 1,400 to many Americans, aid states and cities, and extend unemployment benefits, which is slated to run out to millions in mid-March.

The House Ways and Means Committee took an initial step on Wednesday when it began developing a measure that would continue emergency benefits through the end of August, increasing the weekly benefit premium from $ 300 to $ 400.

With the prospect of additional relief and a decrease in virus cases, some experts say a strong recovery is possible this year. Oxford Economics is forecasting economic growth of 5.9 percent in 2021, compared to a decline of 3.5 percent in the previous year.

According to economists at ZipRecruiter and another major online job board, Employers, employers are already putting out the welcome mat in certain areas.

Ms. Pollak said employer posts at ZipRecruiter in the past few days have offered hope. “We have seen employers exceed all of our expectations and show a lot of exuberance,” she said. “There are clear differences between different industries.”

In addition to strength in industries that benefit from the stay-at-home trend, such as B. Warehousing and deliveries, the recruitment of engineering, professional and business services has recently shown signs of life.

“Companies are looking to the future and are somewhat optimistic,” said Ms. Pollak.

AnnElizabeth Konkel, an economist at Indeed Hiring Lab, added that demand for pharmacists was up 23 percent year-over-year while openings for drivers were up 18 percent. “Everything is directly related to the pandemic,” said Ms. Konkel.

Nevertheless, there were regional differences. In cities like Washington, Seattle, Boston, and San Francisco, where many people work remotely, there were fewer vacancies in some areas than in places with more people back in the office.

“People don’t come to their local café on their way to work or stop at a store to pick up something when they work at home,” said Ms. Konkel, and that affects attitudes.

Restaurant openings have declined for a year, as have positions in arts and entertainment, hospitality and tourism.

At ZipRecruiter, the energy industry posted more jobs after heavy losses at the beginning of the pandemic. Manufacturing has also seen more openings lately.

“Some of the losers are finally coming back a bit,” said Ms. Pollak. “But so many industries are impossible to resume while the pandemic continues.”

Categories
Business

Vaccine ramp up most likely not sufficient to handle UK virus variant

An increase in vaccinations in the coming weeks alone may not be enough to contain the spread of a coronavirus variant, which was first reported in the UK in December and has now emerged in the US, said Scott Gottlieb, former commissioner for food and drug delivery.

The emergence of variants could complicate efforts to reopen the economy in the United States, which, according to Johns Hopkins University, had at least 475,000 virus deaths more than any other country.

The UK first reported the strain known as B117 to the World Health Organization in December, and now there are 971 cases in 37 US states, according to the Centers for Disease Control and Prevention.

“Right now they are shipping 11 million cans a week in states. That will likely increase,” said Gottlieb, who served as FDA chief under former President Donald Trump from 2017 to 2019, in CNBC’s “The News with Shepard Smith”. on Thursday. “So we’re increasing the vaccination rate across the country. Well, will it be fast enough to get a backstop against B117 – probably not by itself.”

Gottlieb said he doesn’t think travel restrictions could stop the spread of the B117 variant because it can often be too late. A “seasonal setback” in the form of the arrival of spring and summer could help reduce the spread of B117, said Gottlieb, a director of Pfizer, whose Covid vaccine is sold in the United States

He said that hopefully a combination of this and increasing vaccinations will include the variant in most parts of the country, although there may be hotspots in southern parts of California and Florida.

Categories
Business

AstraZeneca’s Vaccine Does Not Work Effectively Towards Virus Variant in South Africa

South Africa stopped using the AstraZeneca-Oxford coronavirus vaccine on Sunday after it was found the vaccine did not protect volunteers in clinical trials from mild or moderate illnesses caused by the more contagious variant of the virus first observed there.

The results were a devastating blow to the country’s efforts to fight the pandemic.

Scientists in South Africa said Sunday that a similar problem existed for people infected with previous versions of the coronavirus: the immunity they gained naturally did not seem to protect them from mild or moderate cases than what they were known to have Variant were re-infected as B.1.351.

The developments that occurred almost a week after a million doses of the AstraZeneca-Oxford vaccine hit South Africa were a huge blow to the country, where more than 46,000 people are known to have died from the virus.

They were also another sign of the dangers posed by new mutations in the coronavirus. Variant B.1.351 has spread to at least 32 countries, including the USA.

The number of cases evaluated as part of the studies outlined by South African scientists on Sunday was small, making it difficult to determine exactly how effective the vaccine might or might not be against the variant.

And because the clinical trial participants studied were relatively young and likely not to get seriously ill, it was impossible for the scientists to determine whether the variant affected the AstraZeneca-Oxford vaccine’s ability to protect against severe Covid-19, hospitalization, or death.

However, the scientists said they believed the vaccine might protect against more severe cases based on the immune responses seen in blood samples from people who were given it. If further studies show this is the case, South African health officials will consider resuming use of the AstraZeneca-Oxford vaccine, they said.

The new research results were not published in a scientific journal. The discovery that the AstraZeneca-Oxford product has only minimal effectiveness in preventing mild and moderate cases of the new variant contributed to the growing evidence that B.1.351 makes current vaccines less effective.

Pfizer and Moderna have both said that preliminary laboratory studies show that while their vaccines are still protective, they are less effective against B.1.351. Novavax and Johnson & Johnson have also sequenced test samples from their clinical trial participants in South Africa, where B.1.351 caused the vast majority of cases, and both reported less efficacy than in the US.

“These results are really a reality check,” said Shabir Madhi, a virologist at Witwatersrand University who conducted the AstraZeneca-Oxford vaccine study in South Africa, of the results released on Sunday.

The pause in the introduction of the AstraZeneca-Oxford vaccine in the country means that first deliveries are now being made in warehouses.

Instead, South African health officials said they would be vaccinating health workers with the Johnson & Johnson vaccine in the coming weeks, which has shown strong effectiveness in preventing severe cases and hospitalizations caused by the new variant.

Johnson & Johnson has applied for an emergency permit in South Africa. However, the local health authorities said that some health workers could receive the vaccine before its approval as part of an ongoing study.

In the AstraZeneca-Oxford study in South Africa, around 2,000 participants received either two doses of the vaccine or placebo injections.

There was virtually no difference in the number of people in the vaccine and placebo groups infected with B.1.351, suggesting that the vaccine did little to protect against the new variant. Nineteen of the 748 people in the group who received the vaccine were infected with the new variant, compared with 20 of 714 people in the group who were given a placebo.

This equates to a vaccine effectiveness of 10 percent, although the scientists didn’t have enough statistical confidence to know for sure whether that figure would apply to more people.

The researchers also conducted laboratory experiments on blood samples from people who had been vaccinated and found a significant reduction in the levels of activity of vaccine-generated antibodies to the B.1.351 variant compared to other lineages.

Aside from the disturbing news about the AstraZeneca-Oxford vaccine, Dr. Madhi on evidence that previous infection from previous versions of the coronavirus did not protect people in South Africa from variant B.1.351.

To determine who was previously infected with the coronavirus, the researchers tested blood samples from people who had participated in a study of the Novavax vaccine but who were given placebo shots rather than the vaccine itself.

The researchers compared the infection levels of the new variant in people who were shown to have previously had Covid-19 with the infection levels in people who did not and found no difference.

Dr. Madhi wrote on a slide presented on Sunday evening that “an earlier infection by ‘original’ variants of SARS-CoV-2 does NOT protect against mild and moderate Covid-19 from the B.1.351 variant”.

He said it was possible that the B.1.351 variant’s potential to evade immune responses in previously infected people was at least partially responsible for why South Africa has suffered such a devastating second wave of the virus in recent months.

Oxford University researchers admitted on Sunday that the vaccine offers “minimal protection” against mild or moderate cases with variant B.1.351. They are working on a new version of the vaccine that can protect against the most dangerous mutations of variant B.1.351 and hope that it will be ready in the fall.

“This study confirms that, as expected, the pandemic coronavirus will find ways to spread further in vaccinated populations,” Andrew Pollard, lead investigator for the Oxford vaccine study, said in a statement. “Given the encouraging results of other studies in South Africa using a similar viral vector, vaccines can continue to reduce the burden on health systems by preventing serious diseases.”

Moderna has also started developing a new form of its vaccine that can be used as a booster shot against the variant in South Africa.

B.1.351 has become the dominant form of the virus in South Africa and has been found in several dozen countries. A small number of cases have been reported in South Carolina, Maryland, and Virginia.

Scientists believe that B.1.351 is better able to evade antibodies produced by vaccines because it has acquired a mutation known as E484K that makes it difficult for antibodies to capture the virus and prevent it from entering cells.

Novavax said its vaccine was almost 50 percent effective in preventing Covid-19 in its South Africa study. Johnson & Johnson reported that its single vaccine was 57 percent effective in preventing moderate to severe Covid-19 in South Africa, although it still offered full protection against hospitalization and death after four weeks.

Another fast-spreading variant of the virus, known as B.1.1.7 and first identified in the UK, does not appear to affect the vaccines. All five leading vaccines, and most recently AstraZeneca’s product, were found to offer similar protection against B.1.1.7 when compared to previous lines of the virus.

AstraZeneca’s vaccine has been approved by around 50 countries, including the UK, which has found dozens of cases of the variant first seen in South Africa.

In the US, regulators are waiting for data from a large late-stage clinical trial of the AstraZeneca-Oxford vaccine, which is expected to be published in March.

Categories
Business

Energy, Patriotism and 1.Four Billion Individuals:How China Beat the Virus and Roared Again

The Chinese Communist Party reached deep into private business and the broader population to drive a recovery, an authoritarian approach that has emboldened its top leader, Xi Jinping.

The order came on the night of Jan. 12, days after a new outbreak of the coronavirus flared in Hebei, a province bordering Beijing. The Chinese government’s plan was bold and blunt: it needed to erect entire towns of prefabricated housing to quarantine people, a project that would start the next morning.

Part of the job fell to Wei Ye, the owner of a construction company, which would build and install 1,300 structures on commandeered farmland.

Everything — the contract, the plans, the orders for materials — was “all fixed in a few hours,” Mr. Wei said, adding that he and his employees worked exhaustively to meet the tight deadline.

“There is pressure, for sure,” he said, but he was “very honored” to do his part.

In the year since the coronavirus began its march around the world, China has done what many other countries would not or could not do. With equal measures of coercion and persuasion, it has mobilized its vast Communist Party apparatus to reach deep into the private sector and the broader population, in what the country’s leader, Xi Jinping, has called a “people’s war” against the pandemic — and won.

China is now reaping long-lasting benefits that few expected when the virus first emerged in the central Chinese city of Wuhan and the leadership seemed as rattled as at any moment since the Tiananmen Square crackdown in 1989.

The success has positioned China well, economically and diplomatically, to push back against the United States and others worried about its seemingly inexorable rise. It has also emboldened Mr. Xi, who has offered China’s experience as a model for others to follow.

While officials in Wuhan initially dithered and obfuscated for fear of political reprisals, the authorities now leap into action at any sign of new infections, if at times with excessive zeal. In Hebei this January, the authorities deployed their well-honed strategy to test millions and isolate entire communities — all with the goal of getting cases, officially only dozens a day in a population of 1.4 billion, back to zero.

The government has poured money into infrastructure projects, its playbook for years, while extending loans and tax relief to support business and avoid pandemic-related layoffs. China, which sputtered at the beginning of last year, is the only major economy that has returned to steady growth.

When it came to developing vaccines, the government offered land, loans and subsidies for new factories to make them, along with fast-tracking approvals. Two Chinese vaccines are in mass production; more are on the way. While the vaccines have shown weaker efficacy rates than those of Western rivals, 24 countries have already signed up for them since the pharmaceutical companies have, at Beijing’s urging, promised to deliver them more quickly.

Other nations, like New Zealand and South Korea, have done well containing the virus without heavy-handed measures that would be politically unacceptable in a democratic system. To China’s leaders, those countries do not compare.

Beijing’s successes in each dimension of the pandemic — medical, diplomatic and economic — have reinforced its conviction that an authoritarian capacity to quickly mobilize people and resources gave China a decisive edge that other major powers like the United States lacked. It is an approach that emphasizes a relentless drive for results and relies on an acquiescent public.

The Communist Party, in this view, must control not only the government and state-owned enterprises, but also private businesses and personal lives, prioritizing the collective good over individual interests.

“They were able to pull together all of the resources of the one-party state,” said Carl Minzner, a professor of Chinese law and politics at Fordham University. “This of course includes both the coercive tools — severe, mandatory mobility restrictions for millions of people — but also highly effective bureaucratic tools that are maybe unique to China.”

In so doing, the Chinese Communist authorities suppressed speech, policed and purged dissenting views and suffocated any notion of individual freedom or mobility — actions that are repugnant and unacceptable in any democratic society.

Among the Communist Party leaders, a sense of vindication is palpable. In the final days of 2020, the seven members of the Politburo Standing Committee, the country’s top political body, gathered in Beijing for the equivalent of an annual performance review, where in theory they can air criticisms of themselves and their colleagues.

Far from even hinting at any shortcomings — the rising global distrust toward China, for example — they exalted the party leadership.

“The present-day world is undergoing a great transformation of the kind not seen for a century,” Mr. Xi told officials at another meeting in January, “but time and momentum are on our side.”

In recent weeks, as new cases kept emerging, the government’s cabinet, the State Council, issued a sweeping new directive. “There cannot be a shred of neglect about the risk of resurgence,” it said.

The dictates reflected the micromanaged nature of China’s political system, where the top leaders have levers to reach down from the corridors of central power to every street and even apartment building.

The State Council ordered provinces and cities to set up 24-hour command centers with officials in charge held responsible for their performance. It called for opening enough quarantine centers not just to house people within 12 hours of a positive test, but also to strictly isolate hundreds of close contacts for each positive case.

Cities with up to five million people should create the capacity to administer a nucleic test to every resident within two days. Cities with more than five million could take three to five days.

The key to this mobilization lies in the party’s ability to tap its vast network of officials, which is woven into every department and agency in every region.

The government can easily redeploy “volunteers” to new hot spots, including more than 4,000 medical workers sent to Hebei after the new outbreak in January. “A Communist Party member goes to the frontline of the people,” said Bai Yan, a 20-year-old university student, who has ambitions to join the party.

Zhou Xiaosen, a party member in a village outside of Shijiazhuang, a city of 11 million people that was among those locked down, said that those deputized could help police violations, but also assist those in need. “If they need to go out to buy medicine or vegetables, we’ll do it for them,” he said.

The government appeals to material interests, as well as to a sense of patriotism, duty and self-sacrifice.

The China Railway 14th Bureau Group, a state-owned contractor helping build the quarantine center near Shijiazhuang, drafted a public vow that its workers would spare no effort. “Don’t haggle over pay, don’t fuss about conditions, don’t fall short even if it’s life or death,” the group said in a letter, signed with red thumb prints of employees.

Updated 

Feb. 5, 2021, 2:21 a.m. ET

The network also operates in part through fear. More than 5,000 local party and government officials have been ousted in the last year for failures to contain the coronavirus on their watch. There is little incentive for moderation.

Residents of the northeastern Chinese city of Tonghua recently complained after officials abruptly imposed a lockdown without enough preparations for supplying food and other needs. When a villager near Shijiazhuang tried to escape quarantine to buy a pack of cigarettes, a zealous party chief ordered him tied to a tree.

“Many measures seemed over the top, but as far as they’re concerned it was necessary to go over the top,” said Chen Min, a writer and former Chinese newspaper editor who was in Wuhan throughout its lockdown. “If you didn’t, it wouldn’t produce results.”

The anger has faded over the government’s inaction and duplicity early in the crisis, the consequence of a system that suppresses bad news and criticism. China’s success has largely drowned out dissent from those who would question the party’s central control. The authorities have also reshaped the public narrative by warning and even imprisoning activists who challenged its triumphant version of events.

In the beginning, the pandemic seemed to expose “the fundamental pathologies of Xi-style governance,” said Jude Blanchette, a researcher at the Center for Strategic and International Studies in Washington.

“In fact, with time and hindsight, we see that the system performed in large part as Xi Jinping was hoping it would do,” he added.

The measures in Hebei worked quickly. At the start of February, the province recorded its first day in a month without a new coronavirus infection.

In many countries, debates have raged over the balance between protecting public health and keeping the economy running. In China, there is little debate. It did both.

Even in Wuhan last year, where the authorities shuttered virtually everything for 76 days, they allowed major industries to continue operating, including steel plants and semiconductor factories. They have replicated that strategy when smaller outbreaks have occurred, going to extraordinary lengths to help businesses in ways large and small.

China’s experience has underscored the advice that many experts have suggested but few countries have followed: The more quickly you bring the pandemic under control, the more quickly the economy can recover.

While the economic pain was severe early in the crisis, most businesses closed for only a couple of weeks, if at all. Few contracts were canceled. Few workers were laid off, in part because the government strongly discouraged companies from doing so and offered loans and tax relief to help.

“We coordinated progress in pandemic control and economic and social development, giving urgency to restoring life and production,” Mr. Xi said last year.

Zhejiang Huayuan Automotive Parts Company missed only 17 days of production. With the help of regional authorities, the company hired buses to bring back workers, who had scattered for the Lunar New Year holiday and could not return easily since much of the country was locked down at the beginning. Government passes allowed the buses through checkpoints restricting travel.

Workers were only allowed to go back and forth between the factory and dormitories, their temperatures checked frequently. BYD, a large customer, started manufacturing face masks and shipped supplies to Huayuan.

Soon, the company had more orders than it could handle.

An ambulance manufacturer in Anhui Province increased production immediately, buying screws, bolts and other fasteners that Huayuan produces. Then Chinese automakers started needing them as the virus spread and overseas suppliers shut down.

“We just said no to clients who only wanted standard parts — we wanted to sell more specialized parts, with higher profit,” said Chen Xiying, the company’s deputy general manager. “Clients who were slow to pay we rejected outright.”

Like China itself, Huayuan rebounded quickly. By April, it had ordered nearly $10 million of new equipment to start a second, highly automated production line. It plans to add 47 technicians to its work force of 340.

Before the pandemic, multinationals were looking beyond China for their operations, in part prodded by the Trump administration’s trade war with Beijing. The virus itself added to fears about dependence on Chinese supply chains.

The pandemic, though, only reinforced China’s dominance, as the rest of the world struggled to remain open for business.

Last year, China unexpectedly surpassed the United States as a destination for foreign direct investment for the first time, according to the United Nations Conference on Trade and Development. Worldwide, investments plummeted 42 percent, while in China they grew by 4 percent.

“Despite the human cost and disruption, the pandemic in economic terms was a blessing in disguise for China,” said Zhu Ning, deputy dean of the Shanghai Advanced Institute of Finance.

Last February, while the coronavirus ravaged Wuhan, one of the country’s biggest vaccine manufacturers, Sinovac Biotech, was in no position to develop a new vaccine to stop it.

The company lacked a high-security lab to conduct the risky research needed. It had no factory that could produce the shots, nor the funds to build one.

So the company’s chief executive, Yin Weidong, reached out to the government for help. On Feb. 27, he met with Cai Qi, a member of China’s Politburo, and Chen Jining, the mayor of Beijing and an environmental scientist.

After that, Sinovac had everything it needed.

The officials gave its researchers access to one of the country’s safest labs. They provided $780,000 and assigned government scientists to help.

They also cleared the way for the construction of a new factory in a district of Beijing. The city donated the land. The Bank of Beijing, in which the municipality is a major shareholder, offered a low-interest $9.2 million loan.

When Sinovac needed fermentation tanks that typically take 18 months to import from abroad, the government ordered another manufacturer to work 24 hours a day to make them instead.

It was the sort of all-of-government approach that Mr. Xi outlined at a Politburo Standing Committee meeting two days after Wuhan was locked down. He urged the country to “accelerate the development of therapeutic drugs and vaccines,” and Beijing broadly showered resources.

CanSino Biologics, a private company, partnered with the People’s Liberation Army, working with little rest to produce the first trial doses by March. Sinopharm, a state-owned pharmaceutical company, got government funding in three and a half days to build a factory.

Mr. Yin of Sinovac called the project “Operation Coronavirus” in keeping with the wartime rhetoric of the country’s fight against the outbreak. “It was only under such comprehensive conditions that our workshop could be put into production,” he told The Beijing News, a state-controlled newspaper.

Less than three months after Mr. Yin’s Feb. 27 meeting, Sinovac had created a vaccine that could be tested in humans and had built a giant factory. It is churning out 400,000 vaccines a day, and hopes to produce as many as one billion this year.

The crash course to vaccinate a nation ultimately opened a different opportunity.

With the coronavirus largely stamped out at home, China could sell more of its vaccines abroad. They “will be made a global public good,” Mr. Xi promised the World Health Assembly last May.

Although officials bristle at the premise, “vaccine diplomacy” has become a tool to assuage some of the anger over China’s missteps, helping shore up its global standing at a time when it has been under pressure from the United States and others.

“This is where China can come in and look like a real savior, like a friend in need,” said Ray Yip, a former head of the Bill and Melinda Gates Foundation in China.

China’s efficiency at home has not translated into an easy triumph abroad. Chinese vaccines have lower efficacy rates. Officials in Brazil and Turkey have complained about delays. Still, many countries that have so far signed up for them have acknowledged that they could not afford to wait months for those made by the Americans or Europeans.

On Jan. 16, Serbia became the first European country to receive Chinese vaccines, some one million doses from Sinopharm. The country’s president, Aleksandr Vučić, stood in chilly winds with the Chinese ambassador to welcome the first planeload of supplies.

He told reporters that he was “not afraid to brag” of the country’s relationship with China.

“I’m proud of that and will invest more and more of our time and efforts to create and even improve our great relationship with the Chinese leadership and the Chinese people.”

Coral Yang, Amber Wang, Claire Fu and Elsie Chen contributed research.

Categories
Health

W.H.O. consultants investigating the origin of the virus go to a lab in Wuhan.

A team of experts from the World Health Organization studying the causes of the pandemic visited a research center in Wuhan, China on Wednesday that has been the subject of several unsubstantiated theories about the coronavirus.

WHO scientists met with staff at the center, the Wuhan Institute of Virology, which houses a state-of-the-art laboratory known for its research on coronaviruses.

The institute came under scrutiny last year when the Trump administration advocated the unsubstantiated theory that the virus may have leaked from a government-run laboratory in China. But many high-ranking American officials have privately said that evidence suggesting a laboratory accident is primarily circumstantial.

Most scientists agree that the coronavirus most likely occurred in nature and spread from animals to humans. Peter Daszak, one of the experts on the WHO team, described the conversation on Wednesday at the Wuhan Institute as open. “Important questions asked and answered,” he wrote on Twitter, without giving details.

One of the people the WHO team met was Shi Zhengli, known as China’s “bat woman” for her study of coronaviruses found in bats. In June, Dr. Shi first voiced fears that the virus may have leaked from the lab, according to an interview with Scientific American. Later checks showed that none of the gene sequences matched the viruses examined by the staff.

Separately, China announced on Wednesday that it would provide 10 million Covid-19 vaccines to Covax, a global body promoting equitable access to coronavirus vaccinations.

The decision is “another important step China has taken to promote fair distribution of vaccines,” said Wang Wenbin, a foreign ministry spokesman.

He also said the World Health Organization has started reviewing emergency vaccine approval. It was unclear what vaccines Mr. Wang was referring to. Two vaccines – manufactured by Chinese companies Sinovac and Sinopharm – have been approved for use in China.

Categories
Business

The AstraZeneca vaccine is proven to drastically reduce transmission of the virus.

Developed by Oxford University and AstraZeneca, the vaccine not only protects people from serious illness and death, but also significantly slows down the transmission of the virus, according to a new study – a finding that underscores the importance of mass vaccination as a way out of the pandemic.

The study by researchers at Oxford University is the first to document evidence that any coronavirus vaccine can reduce transmission of the virus.

Researchers measured the effects on transmission by wiping participants down each week to look for signs of the virus. In the absence of a virus, it cannot be spread even if someone is infected. And they found a 67 percent reduction in positive swabs among those vaccinated.

The results, detailed by Oxford and AstraZeneca researchers in a non-peer-reviewed manuscript, found that the vaccine could reduce transmission by nearly two-thirds.

Matt Hancock, the UK Health Secretary, hailed the results on Wednesday as “absolutely outstanding”.

“We now know that the Oxford vaccine will also reduce transmission and help us all get out of this pandemic,” Hancock said in an interview with the BBC on Wednesday morning.

The results, he said, “should give everyone confidence that this shock will not only serve to protect you, but also to keep you from passing the virus on to others.”

Some scientists studying the limited information published warned that further analysis of the data would be needed before such broad conclusions could be drawn.

“While this would be extremely welcome news, we need more data before this can be confirmed, so it is important that we all continue to follow social distancing guidelines after vaccination,” said Dr. Doug Brown, executive director of the British Immunology Society.

The Oxford and AstraZeneca researchers also found that a single dose of the vaccine was 76 percent effective against Covid-19. The data was measured three months after the first shot, with no initial three week period required for the protection to take effect.

The encouraging results support the UK and other countries strategy of prioritizing the provision of as many first doses of vaccine as possible and ignore concerns that people will receive their second doses later than originally planned.

The latest data does not affect the debate over whether to further reduce doses of the two US-approved vaccines Pfizer-BioNTech and Moderna, as the data on AstraZeneca’s candidates cannot be transferred to other vaccines.

Some scientists have urged the United States to follow the example of the UK and other countries who have chosen to postpone the second dose of vaccine for up to 12 weeks. But U.S. federal officials refused, saying such a move would not be supported by clinical trial data for the two vaccines currently available nationwide. Tuesday’s results could add to pressure on US health officials to postpone AstraZeneca’s second dose of vaccine, even though it has not yet been approved by the country.

The vaccine appeared to be more effective when the interval between the two shots was longer than the four-week interval originally intended, the Oxford and AstraZeneca researchers found. Among clinical trial participants who received two standard strength doses at least three months apart, the vaccine was 82 percent effective, compared with 55 percent when the doses were given less than six weeks apart.

Covid19 vaccinations>

Answers to your vaccine questions

Am I eligible for the Covid vaccine in my state?

Currently more than 150 million people – almost half of the population – can be vaccinated. But each state makes the final decision on who goes first. The country’s 21 million healthcare workers and three million long-term care residents were the first to qualify. In mid-January, federal officials asked all states to open eligibility to anyone over 65 and adults of any age with medical conditions that are at high risk of becoming seriously ill or dying of Covid-19. Adults in the general population are at the end of the line. If federal and state health authorities can remove bottlenecks in the distribution of vaccines, everyone over the age of 16 is eligible as early as spring or early summer. The vaccine has not been approved in children, although studies are ongoing. It can take months before a vaccine is available to anyone under the age of 16. For the latest information on vaccination guidelines in your area, see your state health website

Is the Vaccine Free?

You shouldn’t have to pay anything out of pocket to get the vaccine, despite being asked for insurance information. If you don’t have insurance, you should still get the vaccine for free. Congress passed law this spring banning insurers from applying cost-sharing such as a co-payment or deductible. It consisted of additional safeguards prohibiting pharmacies, doctors, and hospitals from charging patients, including uninsured patients. Even so, health experts fear that patients will end up in loopholes that make them prone to surprise bills. This may be the case for people who are charged a doctor’s visit fee with their vaccine, or for Americans who have certain types of health insurance that are not covered by the new regulations. When you get your vaccine from a doctor’s office or emergency clinic, talk to them about possible hidden costs. To make sure you don’t get a surprise invoice, it is best to get your vaccine at a Department of Health vaccination center or local pharmacy as soon as the shots become more widely available.

Can I choose which vaccine to get?How long does the vaccine last? Do I need another next year?

That is to be determined. It is possible that Covid-19 vaccinations will become an annual event just like the flu vaccination. Or the vaccine may last longer than a year. We’ll have to wait and see how durable the protection from the vaccines is. To determine this, researchers will track down vaccinated people to look for “breakthrough cases” – those people who get Covid-19 despite being vaccinated. This is a sign of a weakening of protection and gives researchers an indication of how long the vaccine will last. They will also monitor the levels of antibodies and T cells in the blood of people who have been vaccinated to see if and when a booster shot might be needed. It is conceivable that people might need boosters every few months, once a year, or just every few years. It’s just a matter of waiting for the data.

Does my employer need vaccinations?Where can I find out more?

A vaccination strategy that cuts doses by three months “might be the optimum for pandemic vaccine rollout when supplies are limited in the short term,” the researchers wrote.

The newly published study builds on data published late last year. The vaccine was found to be 62 percent effective at two standard strength doses. In these initial findings, the vaccine effectiveness was 90 percent much higher when the first dose of the vaccine was given at half strength.

The researchers from Oxford and AstraZeneca initially attributed the different levels of effectiveness to the lower strength of the initial dose. Gradually, however, they came to a different conclusion: the time between doses was the more likely explanation.

In the United States, the Food and Drug Administration is waiting for data from a clinical trial that involved around 30,000 participants, mostly Americans. The results of this study are expected later this month.

The study is expected to provide AstraZeneca with enough safety data to enable it to obtain approval to make the emergency vaccine available by early March.

The United States has agreed to purchase 300 million doses of the vaccine from AstraZeneca, but neither the company nor the federal government has indicated when and in what quantities those doses will be available after the vaccine is approved.

Categories
World News

As Virus Variants Unfold, ‘No One Is Protected Till Everybody Is Protected’

KAPSTADT, Südafrika – Als gefährliche Variante des in Südafrika erstmals entdeckten Coronavirus erkrankt und tötet Tausende im ganzen Land. Jan Matsena ist jeden Tag aufgetaucht, um die Regale in einem Supermarkt in Kapstadt zu füllen, und hat Angst, dass auch er es fangen wird .

Ein Nachbar starb im Dezember, dann ein Mitarbeiter in diesem Monat. Jetzt wartet Herr Matsena auf einen Impfstoff, damit er nach Hause in seine Gemeinde zurückkehren und seine kleine Tochter wieder festhalten kann. Aber in Südafrika, dem Land, das bisher am härtesten von der Variante betroffen war, haben die Impfungen noch nicht begonnen.

“Das Warten auf diesen Impfstoff hat lange gedauert”, sagte Matsena, ein erstmaliger Vater, der aus Angst, sie zu entlarven, von seiner Familie getrennt gelebt hat. „Menschen sterben, Menschen verlieren Arbeitsplätze. Es ist ein Trauma. “

Während weltweit mehr als 90 Millionen Menschen geimpft wurden, erhielten laut der Weltgesundheitsorganisation nur 25 in ganz Afrika südlich der Sahara, einer Region mit etwa 1 Milliarde Menschen, Dosen außerhalb von Arzneimittelstudien.

Da jedoch neue Varianten wie die in Südafrika entdeckte in mehr Länder – einschließlich der USA – migrieren, wird immer klarer, dass die Tragödie für ärmere Länder zu einer Tragödie für jedes Land werden könnte. Je weiter sich das Virus verbreitet und je länger es dauert, Menschen zu impfen, desto größer ist die Chance, dass es weiterhin auf eine Weise mutiert, die die ganze Welt gefährdet.

Jüngste Studien legen nahe, dass mindestens vier Impfstoffe, die eine Infektion mit dem ursprünglichen Virus wirksam verhindern, gegen die in Südafrika gefundene Variante nicht so gut abschnitten. Diese Variante ist auch ansteckender – wie auch eine andere, die in Großbritannien entdeckt wurde – und macht nach Angaben von Forschern schätzungsweise 90 Prozent aller Fälle in Südafrika aus. Es ist in Dutzenden anderer Länder aufgetaucht.

Die Inokulation veranlasst das Immunsystem, Antikörper gegen das Virus zu bilden. Wenn jedoch Mutationen seine Form ändern, kann das Virus resistenter gegen diese Antikörper werden. Im schlimmsten Fall würde ein Versäumnis, die Ausbreitung des Virus weltweit zu stoppen, mehr Mutationen ermöglichen, die die Wirksamkeit bestehender Impfstoffe beeinträchtigen und sogar geimpfte Populationen anfällig machen könnten.

“Diese Idee, dass niemand sicher ist, bis alle sicher sind, ist nicht nur ein Sprichwort, es ist wirklich wahr”, sagte Andrea Taylor, die stellvertretende Direktorin des Duke Global Health Innovation Center.

Selbst in den optimistischsten Szenarien, sagte Frau Taylor, werde es bei dem gegenwärtigen Produktionstempo bis 2023 nicht genügend Impfstoffe für eine echte weltweite Abdeckung geben. Die aktuellen Rollout-Pläne in ganz Afrika werden voraussichtlich nur 20 bis 35 Prozent der Bevölkerung impfen dieses Jahr, wenn alles gut geht.

Und während einige wohlhabende Länder genug Impfstoffe erhalten haben, um ihre Bevölkerung mehrmals zu versorgen, hat Südafrika nur 22,5 Millionen Dosen für seine 60 Millionen Menschen gesichert, und viele Nationen bleiben weiter zurück.

Diese Ungleichheit ist das Kernstück dessen, was Tedros Adhanom Ghebreyesus, der Leiter der Weltgesundheitsorganisation, sagt, dass es bald zu einem „katastrophalen moralischen Versagen“ kommen könnte, da reiche Nationen sich beeilen, Impfstoffvorräte aufzukaufen, während arme und einkommensschwache Nationen Schwierigkeiten haben Vorräte finden.

Die ersten Millionen Dosen Südafrikas, die von AstraZeneca hergestellt wurden, sollen am Montag dort eintreffen, und die Beamten sagen, dass es bis zu zwei Wochen dauern wird, bis die Schüsse abgegeben werden. Der mit der Universität Oxford entwickelte Impfstoff von AstraZeneca ist derzeit die weltweit günstigste Option, die mit Ländern mit niedrigem und mittlerem Einkommen als Ziel entwickelt wurde. Das Unternehmen hat keine Informationen über seine Wirksamkeit gegenüber der Variante veröffentlicht, wird dies jedoch voraussichtlich bald tun.

Weitere 9 Millionen Dosen sind bei Johnson & Johnson bestellt, dessen Schuss noch keine behördliche Genehmigung hat. Am Freitag gab das Unternehmen bekannt, dass die Wirksamkeit seines Impfstoffs von 72 Prozent in Studien in den USA auf 57 Prozent in Studien in Südafrika gesunken ist.

Es gibt einige ermutigende Anzeichen. Eine wachsende Anzahl vorläufiger Beweise – hauptsächlich aus der blitzschnellen Einführung in Israel – deutet darauf hin, dass Impfstoffe nicht nur in Studien, sondern auch in der realen Welt eine gute Leistung erbringen und neue Infektionen auslösen.

Es bleibt jedoch abzuwarten, wie gut sie dazu beitragen, die bereits im Umlauf befindlichen Varianten einzudämmen. Wissenschaftler hoffen, dass bei Bedarf Impfstoffe modifiziert und Auffrischungsimpfungen entwickelt werden können, um neue Varianten anzugehen, aber das braucht Zeit. Und für eine Welt, die darum kämpft, sich zu verbessern, ist Zeit von entscheidender Bedeutung.

Dr. Tulio de Oliveira, Professor und Genetiker an der Nelson Mandela School of Medicine in Durban, der zur Entdeckung der ursprünglich in Südafrika gefundenen Variante beigetragen hatte, sagte, dass ihre Entstehung als Weckruf dienen sollte.

“Eines der Dinge, die diese Variante für die ganze Welt hervorheben sollte, ist die Notwendigkeit, die Übertragung zu kontrollieren – nicht nur in ihrem eigenen Land, sondern auf der ganzen Welt”, sagte er.

Und während die Nationen sich beeilt haben, ihre Grenzen zu versiegeln, verbreiten sich die Varianten bereits in Dutzenden von Ländern – so wie sich das Virus im letzten Winter den nationalen Grenzen entzogen hat. Brasilien zum Beispiel scheint mindestens zwei besorgniserregende Varianten inkubiert zu haben, die bereits ihre Grenzen überschritten hatten, bevor viele Länder begannen, den Flugverkehr von dort aus zu unterbrechen.

Die Last der Lieferung von Impfstoffen an Länder mit niedrigem und mittlerem Einkommen hängt stark von einer gemeinnützigen Gruppe, Covax, ab, die von einer Koalition internationaler Organisationen gebildet wird.

Obwohl sich mehr als 190 Länder verpflichtet haben, Impfstoffe über Covax zu erhalten, schließen viele von ihnen auch Verträge direkt mit Pharmaunternehmen ab oder gehören multinationalen Gruppen an, die dies tun. Dies droht die Preise zu erhöhen und die Abgabe von Dosen über Covax zu verzögern.

Covax hat angekündigt, für 2021 2,1 Milliarden Dosen gesichert zu haben, aber es ist unklar, wie viele davon tatsächlich im Jahr 2021 geliefert werden.

Die Hoffnung ist, dass die Einführung in ärmere Länder in den nächsten ein oder zwei Monaten ernsthaft beginnen kann.

“Covax ist notwendig, aber nicht ausreichend”, sagte Frau Taylor. „Es ist der einzige Mechanismus, den wir für globales Eigenkapital haben. Wir brauchen es und wir brauchen es, um erfolgreich zu sein. Aber selbst wenn sie erfolgreich sind, bringt es die Länder nicht in die Nähe der Herdenimmunität. “

Orin Levine, Direktor für globale Lieferprogramme bei der Bill and Melinda Gates Foundation, sagte: “Die nackten Tatsachen sind, dass bis Ende dieses Jahres wahrscheinlich 75 Prozent der Bevölkerung in Ländern mit hohem Einkommen geimpft werden”, verglichen mit 25 Prozent in Ländern mit niedrigem Einkommen.

Covid19 Impfungen >

Antworten auf Ihre Impfstofffragen

Bin ich in meinem Bundesstaat für den Covid-Impfstoff berechtigt?

Derzeit können mehr als 150 Millionen Menschen – fast die Hälfte der Bevölkerung – geimpft werden. Aber jeder Staat trifft die endgültige Entscheidung darüber, wer zuerst geht. Die 21 Millionen Beschäftigten im Gesundheitswesen des Landes und drei Millionen Einwohner von Langzeitpflegeeinrichtungen waren die ersten, die sich qualifizierten. Mitte Januar forderten Bundesbeamte alle Bundesstaaten auf, die Berechtigung für alle über 65-Jährigen und für Erwachsene jeden Alters mit Erkrankungen zu öffnen, bei denen ein hohes Risiko besteht, dass sie schwer krank werden oder an Covid-19 sterben. Erwachsene in der Allgemeinbevölkerung stehen am Ende der Reihe. Wenn Gesundheitsbehörden von Bund und Ländern Engpässe bei der Verteilung von Impfstoffen beseitigen können, sind alle ab 16 Jahren bereits im Frühjahr oder Frühsommer förderfähig. Der Impfstoff wurde bei Kindern nicht zugelassen, obwohl derzeit Studien durchgeführt werden. Es kann Monate dauern, bis ein Impfstoff für Personen unter 16 Jahren verfügbar ist. Aktuelle Informationen zu den Impfrichtlinien in Ihrer Region finden Sie auf Ihrer staatlichen Gesundheitswebsite

Ist der Impfstoff frei?

Sie sollten nichts aus eigener Tasche bezahlen müssen, um den Impfstoff zu erhalten, obwohl Sie nach Versicherungsinformationen gefragt werden. Wenn Sie nicht versichert sind, sollten Sie den Impfstoff trotzdem kostenlos erhalten. Der Kongress hat in diesem Frühjahr ein Gesetz verabschiedet, das es Versicherern verbietet, eine Kostenteilung wie eine Zuzahlung oder einen Selbstbehalt anzuwenden. Es bestand aus zusätzlichen Schutzmaßnahmen, die es Apotheken, Ärzten und Krankenhäusern untersagten, Patienten, einschließlich nicht versicherter Patienten, in Rechnung zu stellen. Trotzdem befürchten Gesundheitsexperten, dass Patienten in Schlupflöcher geraten, die sie für Überraschungsrechnungen anfällig machen. Dies kann bei Personen der Fall sein, denen zusammen mit ihrem Impfstoff eine Arztbesuchsgebühr berechnet wird, oder bei Amerikanern, die bestimmte Arten der Krankenversicherung haben, die nicht unter die neuen Vorschriften fallen. Wenn Sie Ihren Impfstoff von einer Arztpraxis oder einer Notfallklinik erhalten, sprechen Sie mit ihnen über mögliche versteckte Kosten. Um sicherzugehen, dass Sie keine Überraschungsrechnung erhalten, ist es am besten, wenn Sie Ihren Impfstoff an einer Impfstelle des Gesundheitsministeriums oder in einer örtlichen Apotheke erhalten, sobald die Aufnahmen breiter verfügbar sind.

Kann ich wählen, welchen Impfstoff ich bekomme?Wie lange hält der Impfstoff? Brauche ich nächstes Jahr noch einen?

Das ist zu bestimmen. Es ist möglich, dass Covid-19-Impfungen genau wie die Grippeimpfung zu einem jährlichen Ereignis werden. Oder es kann sein, dass der Nutzen des Impfstoffs länger als ein Jahr anhält. Wir müssen abwarten, wie dauerhaft der Schutz vor den Impfstoffen ist. Um dies festzustellen, werden Forscher geimpfte Menschen aufspüren, um nach „Durchbruchsfällen“ zu suchen – jenen Menschen, die trotz Impfung an Covid-19 erkranken. Dies ist ein Zeichen für eine Schwächung des Schutzes und gibt Forschern Hinweise darauf, wie lange der Impfstoff hält. Sie werden auch die Spiegel von Antikörpern und T-Zellen im Blut geimpfter Personen überwachen, um festzustellen, ob und wann ein Auffrischungsschuss erforderlich sein könnte. Es ist denkbar, dass Menschen alle paar Monate, einmal im Jahr oder nur alle paar Jahre Booster benötigen. Es geht nur darum, auf die Daten zu warten.

Benötigt mein Arbeitgeber Impfungen?Wo kann ich mehr erfahren?

Für afrikanische Nationen ist das langsame Tempo des Rollouts erschreckend vertraut.

Als eine andere Geißel – HIV / AIDS – jedes Jahr Millionen von Menschen tötete, hatte Afrika die meisten Infektionen und Todesfälle. Dennoch dauerte es mindestens sechs Jahre, bis die in reichen Ländern verfügbare lebensrettende Behandlung den Afrikanern zur Verfügung gestellt wurde.

AIDS hat in einem Jahrzehnt 12 Millionen Menschen in Afrika getötet, obwohl die Sterblichkeit in den USA laut Analysen der Africa Centers for Disease Control and Prevention drastisch gesunken ist. Streitigkeiten über internationale Eigentumsrechte verzögerten die Produktion von mehr antiretroviralen Medikamenten oder kostengünstigen Generika.

Jetzt haben sich Indien und Südafrika zusammengetan, um sich bei der Welthandelsorganisation dafür einzusetzen, dass Pharmaunternehmen ihr geistiges Eigentum an Coronavirus-Impfstoffen teilen müssen, wie dies letztendlich bei der HIV / AIDS-Behandlung der Fall war.

“Was Sie jetzt brauchen, ist die explizite Zusammenarbeit jeder einzelnen Regierung und jedes einzelnen Pharmaunternehmens, die sagt, dass wir uns in einer Pandemie befinden und auf dem Weg zur Katastrophe sind”, sagte Fatima Hassan, eine südafrikanische Menschenrechtsanwältin, die für HIV kämpfte / AIDS-Medikamente und hat jetzt auf Covid-19-Impfstoffe umgestellt. “Wir müssen die Technologie teilen und Milliarden ausgeben, um Billionen zu sparen.”

Solomon Zewdu, stellvertretender Direktor für Gesundheit in Afrika bei der Gates Foundation, sagte, dass Karten und Diagramme, die die weltweiten Impfraten zeigen – wobei Afrika fast völlig abwesend ist – die öffentliche Wut schüren und einige Führungskräfte dazu veranlassen, neben Covax nach zusätzlichen Impfstoffquellen zu suchen.

Laut Nicaise Ndembi, leitende wissenschaftliche Beraterin der afrikanischen Zentren für die Kontrolle und Prävention von Krankheiten, kündigte die Afrikanische Union in diesem Monat den Kauf von 300 Millionen Impfstoffen an, die über die African Medical Supplies Platform der regionalen Behörde verteilt werden sollen.

In Ländern wie Mosambik, Simbabwe und Sambia, in denen angenommen wurde, dass die in Südafrika gefundene Variante zu einem Anstieg der Infektionen führt, haben die Behörden keine klaren Antworten darauf, wann Impfstoffe eintreffen werden.

Südafrika hat unterdessen in seiner Pandemie-Reaktion relativ selbstbewusst reagiert und Schritte unternommen, die innerhalb des Landes zu Kontroversen geführt haben. Präsident Cyril Ramaphosa hat eine Ausgangssperre von 21.00 bis 05.00 Uhr wieder eingeführt, die Teilnahme an Beerdigungen und religiösen Versammlungen eingeschränkt, den Verkauf von Alkohol verboten und Masken in allen öffentlichen Räumen vorgeschrieben. Das Fehlen einer Maske kann zu einer Geldstrafe oder sechs Monaten Gefängnis führen.

Wenn die Impfungen voraussichtlich Mitte Februar beginnen, stehen die Beschäftigten im Gesundheitswesen an erster Stelle, gefolgt von denjenigen, die als am stärksten von schwerer Krankheit bedroht gelten.

Für Herrn Matsena, den Supermarktmitarbeiter, der 31 Jahre alt und gesund ist, könnte es eine lange Wartezeit sein.

“Es wäre besser, wenn es früher ankommen würde, denn jetzt haben die Menschen Angst vor dieser Pandemie”, sagte er. “Es ist schlimmer, viel schlimmer.”

Categories
Business

‘Like Wartime’: Canadian Corporations Unite to Begin Mass Virus Testing

TORONTO – A consortium of some of the country’s largest companies has launched a rapid testing program to protect its 350,000 employees and publish a playbook for business Canada on how to safely reopen.

The program is considered the first of its kind in the group of 7 industrialized nations and has already attracted the attention of the Biden government.

The 12 companies, including Canada’s largest airline and grocery chain, have been working together for four months. Creation of a 400-page instruction manual for performing rapid antigen tests in various work settings. They started testing the tests in their workplaces this month and expect to expand the program to 1,200 small and medium-sized businesses.

They also plan to share their test results with state health officials to significantly increase the number of tests in the country and provide an informal study on the spread of the virus among asymptomatic people.

“It’s like wartime – people come together to do something that is in everyone’s interest,” said Marc Mageau, senior vice president of refining and logistics at Suncor Energy, the country’s largest oil producer, who conducted the tests this month introduced his employees.

The program faces some inherent challenges: After an outbreak last year in the White House, antigen tests were discovered that induce both false negative results and a false sense of security. They are also in short supply in Canada. Some experts feel that they should be reserved for schools and nursing homes rather than non-essential businesses.

While vaccines are considered the world’s best weapon to fight the pandemic, most experts believe it will take months, if not a full year, for Canada to reach the vaccination levels that will allow workplaces to safely return to their pre-Covid surgeries .

Canada is in a second wave of pandemics that has driven infections to record levels and deaths to around 19,800. In response, many parts of the country are on lockdown, restaurants, theaters, and non-essential retail stores are closed.

Canada’s economy contracted about 5 percent during the pandemic. Some industries such as real estate and manufacturing have performed well, but those that depend on public crowds, such as entertainment and hospitality, have seen employment decline.

“Think about downtown Toronto: nobody is there anymore. Entertainment – everything is stopped, ”said Joshua Gans, professor of strategic management at the University of Toronto who served as advisor to and is the author of the project “The Pandemic Information Gap: The Brutal Economy of Covid-19.”

“It is time to figure out how to actually reopen the closed sectors,” he said.

The consortium companies were brought together in the spring by Ajay Agrawal, founder of the University of Toronto’s Creative Destruction Lab. That helps science and technology start-ups. They were inspired by the most Canadian muses: Margaret Atwood, the author.

“How soon can we get a cheap, self-administered test at the drugstore?” Ms. Atwood asked business leaders and others who were tasked with brainstorming ideas for economic recovery during the pandemic during a virtual meeting last May.

The problem, the group noted, was the “information gap” – with no way of telling who an asymptomatic carrier might be, everyone was treated as a potential threat.

Ms. Atwood envisioned something like a home pregnancy test.

“That would be a game changer,” she said.

When the group realized that the government was overwhelmed by the health crisis, they decided to take on the task themselves and form a consortium led by the Creative Destruction Lab.

The group focused on antigen testing because of its speed, price, and utility: you can get results in minutes, don’t require a lab, and can cost anywhere from $ 5 to $ 20 in Canada.

Updated

Jan. 30, 2021, 8:47 p.m. ET

However, they are less accurate and produce more false negative results than the gold standard polymerase chain reaction or PCR tests, which can cost 20 times as much. The three antigen tests approved for use in Canada characterize between 84 percent and 96.7 percent of those infected with the virus.

In the UK, antigen tests used in a mass testing campaign identified only two-fifths of the coronavirus cases detected by PCR testing.

Because of this, many experts in Canada and elsewhere initially argued that it would be wiser to expand PCR testing. However, as the pandemic spread and the country failed to meet its testing goals, that thinking changed, said Dr. Irfan Dhalla, co-chair of the Canadian Advisory Panel on Testing and Screening for Covid-19, which recommended increasing the country’s use of rapid tests.

A rapid antigen test is clearly better than no test at all, as long as it is not used as a free pass, ”said Dr. Dhalla. “Whether it’s a job or a school, you still have to wear a mask and physically distance yourself as much as possible.”

In the long term, the members of the consortium hope that the testing program will help reduce infection rates enough to allow crowded restaurants and boardroom meetings to take place again. In the meantime, however, they plan to use the tests as an extra layer of protection – in addition to wearing masks, social distancing, and pre-screening of staff so those with symptoms can stay home.

The consortium companies also test their employees twice a week to increase the likelihood that positive cases will be picked up.

“Everyone is looking for a silver bullet. We realized that it doesn’t exist. It’s not, ”admitted Laura Rosella, professor of epidemiology at the University of Toronto and advisor to the project.

In September, more than 100 consortium employees began working together at the expense of their companies to come up with a plan. Two retired generals volunteered to manage the logistics.

The coronavirus outbreak>

Things to know about testing

Confused by Coronavirus Testing Conditions? Let us help:

    • antibody: A protein produced by the immune system that can recognize and attach to certain types of viruses, bacteria or other invaders.
    • Antibody test / serology test: A test that detects antibodies specific to the coronavirus. About a week after the coronavirus infects the body, antibodies start appearing in the blood. Because antibodies take so long to develop, an antibody test cannot reliably diagnose an ongoing infection. However, it can identify people who have been exposed to the coronavirus in the past.
    • Antigen test: This test detects parts of coronavirus proteins called antigens. Antigen tests are quick and only take five minutes. However, they are less accurate than tests that detect genetic material from the virus.
    • Coronavirus: Any virus that belongs to the Orthocoronavirinae virus family. The coronavirus that causes Covid-19 is known as SARS-CoV-2.
    • Covid19: The disease caused by the new coronavirus. The name stands for Coronavirus Disease 2019.
    • Isolation and quarantine: Isolation is separating people who know they have a contagious disease from those who are not sick. Quarantine refers to restricting the movement of people who have been exposed to a virus.
    • Nasopharyngeal smear: A long, flexible stick with a soft swab that is inserted deep into the nose to collect samples from the space where the nasal cavity meets the throat. Samples for coronavirus tests can also be obtained with swabs that do not go as deep into the nose – sometimes called nasal swabs – or with mouth or throat swabs.
    • Polymerase chain reaction (PCR): Scientists use PCR to make millions of copies of genetic material in a sample. With the help of PCR tests, researchers can detect the coronavirus even when it is scarce.
    • Viral load: The amount of virus in a person’s body. In people infected with the coronavirus, viral loads can peak before symptoms, if any.

The group was registered as a nonprofit called the CDL Rapid Screening Consortium in November, with each company contributing $ 230,000 in operating costs.

The employees work in teams Researched around 50 different antigen tests around the world, analyzed what was required for a screening program – from staff to number of dresses – and estimated the total cost.

The resulting 400-page user guide includes everything from an example of an employee invitation to participate in the program and a standard consent form, to a detailed shopping list of materials required to run a program.

One of the hurdles was getting tests. They had to get them from the government because they are not yet widely available in Canada and the demand from schools and nursing homes is high.

“Let’s do tests there first,” said Dr. Dhalla, referring to schools, nursing homes and important workplaces. “As we gain experience, we can talk about getting people back to work where working from home is an option.”

In January, five companies began testing the program in environments as diverse as pharmacies and radio stations. So far, around 400 employees have volunteered and nearly 1,900 tests have been carried out. According to Sonia Sennik, the executive director of the Creative Destruction Lab and avid quarterback of the project, only three have made positive returns.

“They didn’t go to work and they might spread something,” said Ms. Sennik. “We interrupted the transmission chain three times.”

The companies found the program reduced employees’ fear of not only getting to work but returning home every day, she said.

“I’m relieved,” said Mohamed Gaballa, an Air Canada official who took the test during a break at Toronto Pearson International Airport. This came up within 15 minutes by email: “Your screening result is negative. You can go on with your day. “

“This has been a missing piece in Canada for far too long,” said Dan Kelly, president and chief executive officer of Canadian Federation of Independent Businesses that represents 110,000 small and medium-sized businesses.

Small businesses face a lot more hurdles to implementing such a program, even if dodging a 400-page manual, he said. There is the cost of the tests, but more importantly the staff to manage them.

Mr. Kelly envisioned that the program would not work in restaurants and busy stores – places where unscreened customers far exceeded the number of employees screened unless they were planned to be tested. But in kitchens, small warehouses, small manufacturing facilities, and offices, “these tests could be very helpful,” he said.

“Under normal circumstances, the idea of ​​small businesses doing employee testing for everything would be a fantasy,” said Kelly, who sits on the federal government’s industry advisory group on Covid-19 testing. “But in this case, given the desperation to remain or remain open among small business owners, there is a potential appetite for it.”

Categories
World News

Alarm in U.Okay. Over Virus Variant Bolsters Case for Lockdown

LONDON – The UK’s disclosure on Friday that a new variant of the virus could be more deadly than the original caused a stir over why such alarming information was released when the evidence was so inconclusive. However, its effects are little discussed: it has silenced those who have called for life to return to normal soon.

The UK government is expected to announce in the coming days that it will extend and tighten the nationwide lockdown imposed by Prime Minister Boris Johnson this month. Schools can remain closed until Easter, while overseas travelers may need to be quarantined in hotels for 10 days.

For Mr Johnson, who has faced relentless pressure from members of his own Conservative Party to relax restrictions, the warning of the variant made a strong case that Britain may be in the middle of a serious new phase of the pandemic – and that it does relaxed constraints now could be disastrous.

While scientists agree that the evidence of the variant’s greater lethality is tentative, inconclusive, and based on limited data, they said it was nonetheless served the government’s purposes in the lockdown debate that Mr Johnson, who spoke between Science and politics have often been drawn to have shown an aversion to tough steps.

“It is strange to make such an announcement, which has dire consequences and clearly affects the general public, without a full dataset and more thorough analysis,” said Lawrence Young, a virologist at Warwick Medical School. “I wonder if it was about reiterating the harsh message that the lockdown must be adhered to and increased border controls justified.”

Devi Sridhar, director of the global public health program at the University of Edinburgh, said, “These preliminary data show why waiver restrictions should be applied carefully and measuredly.”

The interests of scientists and government officials have not always been balanced in Britain’s fight against the pandemic. Tensions have increased when Mr Johnson reopened the economy as scientists warned of new infections.

During his briefing on Downing Street on Friday, Mr Johnson, as some noted, had no choice but to confirm concerns that the new variant beating Britain could not only be more contagious but also more deadly. Hours earlier, a well-known epidemiologist, Neil Ferguson of Imperial College London, told a television journalist Robert Peston that a government scientific committee had concluded that there was a “realistic possibility” that the variant could be 30 percent more deadly than it is the original version of the coronavirus.

The Prime Minister’s initial announcement that the variant could be linked to higher death rates contained few details and did not make it clear how uncertain many experts were about the data. While government scientists later published a summary of studies setting out the possible effects of the variant, the number of deaths they analyzed was small and uncertainties about the data resulted in a wide range of estimates.

“We haven’t seen the evidence, which in itself is worrying,” said David King, a former chief scientific advisor to the government who was critical of Mr Johnson’s handling of the pandemic. “I would have simply welcomed the science with a preprint report.”

Dr. Ferguson himself has become something of a lightning rod during the pandemic. In March last year, his models predicted that the uncontrolled spread of the virus in the UK could cause up to 510,000 deaths. These numbers stunned Mr. Johnson and prompted him to impose the country’s first lockdown despite waiting a week to act.

At the time, some scientists criticized Dr. Ferguson on the grounds that he was too public and that his projections were exaggerated. They accused him of publishing inflated projections of death during previous epidemics. After pressing for repression, he was referred to by the British tabloids as “Professor Lockdown”.

Updated

Jan. 26, 2021, 4:31 p.m. ET

Dr. Ferguson later resigned from the government’s Emergency Scientific Advisory Group (SAGE) after admitting he breached lockdown rules by inviting a woman to his home.

As a member of a key SAGE committee, the Advisory Group on New and Emerging Respiratory Virus Threats, which released a report on the lethality of the variant on Friday evening, Dr. Ferguson played a leading role in alerting the new variant. And with the UK death toll nearing 100,000, its projections don’t look all that fantastic even after multiple lockdowns.

Government scientists defended the decision to publish the results in the interests of transparency. The disclosure reflected the rapidly changing thinking of infectious disease experts about the potential of mutations to change the path of the virus. Variants that were discovered earlier in the pandemic received little public attention.

Still, virologists said they were concerned about the lack of a strong theory about how or why the variant, first discovered in the UK, could lead to more people dying. Among other concerns about the new data – the small number of deaths on which the results were based, and the fact that harrowing conditions in hospitals themselves could lead to higher death rates – was the uncertainty about why this could be more dangerous waiting for more dates you said.

“You can see some mechanism by which the transmission rate would be a little higher,” said Ian Jones, professor of virology at the University of Reading. “But why that should lead to a higher death rate is not so easy to see.”

Mutations in the new variant make it easier to attach to human cells, which makes them even more contagious. Virologists said that the same trait could theoretically allow more cells to be infected than older variants, which could lead to wider infection, which in turn could produce a more aggressive and potentially dangerous immune response.

With no laboratory data to suggest this could happen, scientists said it was far too early to understand the models that point to higher death rates.

Even the most reputable methods of studying the effects of the variant yielded a wide range of additional risk estimates, ranging from having virtually no effect on mortality to increasing the risk of death by 65 percent.

Nonetheless, the fact that so many models evaluated by government scientists suggested higher mortality rates has alarmed scientists.

“For now, overall, I’d say it’s likely valid,” said Paul Hunter, professor of medicine at the University of East Anglia. “I can’t believe that all of these different groups would have drawn the same conclusions and made the same mistakes in controlling possible biases. But it’s not beyond the possibilities. “

Even so, scientists said the new variant would not only reinforce the government’s case for restrictions not yet relaxing, but would also require the same policy measures as previous versions of the virus.

“What more can we do just because we know this is more deadly?” Professor Hunter said. “The answer is probably nothing.”